The Angioedema Treatment Market is projected to reach USD 14.32 billion by 2030 from USD 4.00 billion in 2022, at a CAGR of 17.26% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Angioedema Treatment Market.

  • Based on Drugs Type, market is studied across C1 Esterase Inhibitor, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist. The C1 Esterase Inhibitor is further studied across Berinert, Cinryze, Haegarda, and Ruconest. The Kallikrein Inhibitor is further studied across Kalbitor. The Selective Bradykinin B2 Receptor Antagonist is further studied across Firazyr. The C1 Esterase Inhibitor is projected to witness significant market share during forecast period.

  • Based on Route of Administration, market is studied across Injections and Oral. The Oral is projected to witness significant market share during forecast period.

  • Based on End-User, market is studied across Clinics, Hospitals, and Research Organizations. The Research Organizations is projected to witness significant market share during forecast period.

  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Angioedema Treatment Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Angioedema Treatment Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

The report offers valuable insights on the following aspects:

  1. Market Penetration: It provides comprehensive information about key players’ market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast for the Angioedema Treatment Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Angioedema Treatment Market?
  3. What is the competitive strategic window for identifying opportunities in the Angioedema Treatment Market?
  4. What are the latest technology trends and regulatory frameworks in the Angioedema Treatment Market?
  5. What is the market share of the leading vendors in the Angioedema Treatment Market?
  6. Which modes and strategic moves are suitable for entering the Angioedema Treatment Market?